# Single and Multiple Ascending Dose Study of AMG 171 in Subjects With Obesity

> **NCT04199351** · PHASE1 · TERMINATED · sponsor: **Amgen** · enrollment: 60 (actual)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** AMG 171
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04199351
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-12-13
- **Primary completion:** 2021-09-10
- **Final completion:** 2021-09-10
- **Target enrollment:** 60 (ACTUAL)
- **Why stopped:** Amgen determined the totality of the data does not support continuation of AMG 171 development program for treatment of Obesity. No safety concerns identified.
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04199351

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04199351, "Single and Multiple Ascending Dose Study of AMG 171 in Subjects With Obesity". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04199351. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*